Related Experiment Video
Updated: Jun 1, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Expression of C-erbb-2 and epidermal growth-factor receptor in breast-carcinoma - prognostic value and correlation
M Noguchi1, Y Mizukami, K Kinoshita
1KANAZAWA UNIV HOSP,SCH MED,PATHOL SECT,KANAZAWA,ISHIKAWA 920,JAPAN. KANAZAWA UNIV HOSP,SCH MED,DEPT SURG 2,KANAZAWA,ISHIKAWA 920,JAPAN.
Abstract:
We examined epidermal growth factor receptor (EGFR) and/or c-erbB-2 expression, clinicopathological variables, silver-stained nuclear organizer region (Ag-NOR) counts, and their prognostic values in 93 patients with operable breast carcinoma. There was no significant correlation between c-erbB-2 and EGFR expression. Increased Ag-NOR counts were significantly associated with positive c-erbB-2 expression, but not with positive EGFR expression. However, co-expression of both proteins was significantly correlated with axillary lymph node metastases. Significant differences in survival were found between groups of patients stratified by tumor size, histological grade, axillary lymph node metastases, c-erbB-2, and EGFR expression by univariate analysis. In addition, c-erbB-2 and EGFR expression in combination was strongly correlated with decreased survival. However, only axillary lymph node metastases and age appeared to be independent prognostic factors by multivariate analysis. We therefore conclude that the prognostic value of c-erbB-2 and EGFR expression is limited in breast carcinoma.
